Cisplatin – Uses, Dosage, Side Effects, Interaction

Last updated: February 8, 2026Reviewed date: February 8, 2026Reading time: 75 min read
Patient Tools

Read, save, and share this guide

Use these quick tools to make this medical article easier to read, print, save, or share with a family member.

Cisplatin - Uses, Dosage, Side Effects, Interaction
Patient Mode

Understand this article easily

Switch between simple English and easy Bangla patient notes. This is for education and does not replace a doctor consultation.

Cisplatin is the prototype platinum coordination complex classified as an alkylating agent and used intravenously in the treatment of several forms of cancer. Cisplatin has been associated with a low rate of serum enzyme elevations and with rare cases of clinically apparent, acute liver injury. Cisplatin is a chemotherapy drug used...

For severe symptoms, danger signs, pregnancy, child illness, or sudden worsening, seek urgent medical care.

বাংলা রোগী নোট এখনো যোগ করা হয়নি। পোস্ট এডিটরে “RX Bangla Patient Mode” বক্স থেকে সহজ বাংলা সারাংশ যোগ করুন।

এই তথ্য শিক্ষা ও সচেতনতার জন্য। এটি ডাক্তারি পরীক্ষা, রোগ নির্ণয় বা প্রেসক্রিপশনের বিকল্প নয়।

Article Summary

Cisplatin is the prototype platinum coordination complex classified as an alkylating agent and used intravenously in the treatment of several forms of cancer. Cisplatin has been associated with a low rate of serum enzyme elevations and with rare cases of clinically apparent, acute liver injury. Cisplatin is a chemotherapy drug used to treat testicular, ovarian, bladder, head and neck, lung and cervical cancer. It may also be used to treat other...

Key Takeaways

  • This article explains Mechanism of action in simple medical language.
  • This article explains Indications in simple medical language.
  • This article explains Contraindications in simple medical language.
  • This article explains Dosage in simple medical language.
Educational health guideWritten for patient understanding and clinical awareness.
Reviewed content workflowUse writer and reviewer profiles for stronger trust.
Emergency safety firstUrgent warning signs are highlighted below.

Seek urgent medical care if you notice

These warning signs are general safety guidance. Local emergency numbers and clinical judgment should always come first.

  • Severe symptoms, breathing difficulty, fainting, confusion, or rapidly worsening illness.
  • New weakness, severe pain, high fever, or symptoms after a serious injury.
  • Any symptom that feels urgent, unusual, or unsafe for the patient.
1

Emergency now

Use emergency care for severe, sudden, rapidly worsening, or life-threatening symptoms.

2

See a doctor

Book a professional medical evaluation if symptoms persist, worsen, recur often, affect daily activities, or occur in a high-risk patient.

3

Learn safely

Use this article to understand possible causes, tests, treatment options, prevention, and questions to ask your clinician.

Before reading

RX Patient Tools

Use these quick guides before reading the article, or return to them when you need help preparing questions for a doctor.

Start here Choose the right pathway for symptoms, reports, medicines, or urgent warning signs. Disease article roadmap Read this topic step by step: meaning, symptoms, warning signs, diagnosis, treatment, prevention, and follow-up. Treatment planner Prepare questions about treatment choices, benefits, risks, side effects, and follow-up. Family & caregiver guide Organize symptoms, reports, medicines, questions, and follow-up safely. Nutrition & diet guide Prepare food, hydration, supplement, and medicine-timing questions safely. Prevention guide Organize risk factors, protective habits, screening, and warning signs. Recovery guide Prepare a safe plan for activity, rehabilitation, warning signs, and follow-up.
Definition

Cisplatin is the prototype platinum coordination complex classified as an alkylating agent and used intravenously in the treatment of several forms of cancer. Cisplatin has been associated with a low rate of serum enzyme elevations and with rare cases of clinically apparent, acute liver injury.

Cisplatin is a chemotherapy drug used to treat testicular, ovarian, bladder, head and neck, lung and cervical cancer. It may also be used to treat other cancers. It is best to read this information with our general information about chemotherapy and the type of cancer you have.

Cisplatin, cisplatinum, or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Mechanism of action

Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations.

Cisplatin is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands – directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result – disruption of DNA function and cell death.

Indications

  • For the treatment of metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer.
  • Mantle cell lymphoma that has relapsed (come back) or is refractory (does not respond to treatment).
  • Precursor B lymphoblastic leukemia (a type of acute lymphoblastic leukemia) has relapsed or is refractory.
  • Advanced Ovarian Cancer
  • Ovarian Cancer Metastatic
  • Advanced Bladder cancer
  • Advanced Testicular cancer
  • Metastatic Testicular cancer

Use in Cancer

Cisplatin is approved to be used alone or with other drugs to treat:

  • Bladder cancer. It is used alone in patients with advanced cancer that cannot be treated with other therapies, such as surgery or radiation therapy.
  • Ovarian cancer has spread to other parts of the body. It is used with other drugs in patients who have already had surgery or radiation therapy. It is used alone in patients whose cancer has not gotten better with standard chemotherapy and who have not received previous cisplatin.
  • Testicular cancer has spread to other parts of the body. It is used with other drugs in patients who have already had surgery or radiation therapy.

Cisplatin is also being studied in the treatment of other types of cancer.

Contraindications

  • are allergic to cisplatin, any platinum-containing compounds, or any ingredients of the medication
  • have hearing impairment
  • have reduced bone marrow function (e.g. low white cells)
  • have reduced kidney function
  • Severe hypersensitivity to cisplatin or platinum compounds would preclude its administration; cisplatin is contraindicated in patients who have had severe hypersensitivity reactions, and rechallenge is not a recommendation.
  • Cisplatin has been shown to cross the placenta and may cause fetal harm. Women of reproductive age should use reliable contraception during treatment and up to a year from the final treatment date.
  • Cisplatin is also present in the breast milk of lactating women on a cisplatin regimen. Breastfeeding is not recommended during treatment. If hypersensitivity occurs, the provider should discontinue cisplatin immediately.
  • a bad infection
  • acute leukemia
  • low amount of magnesium in the blood
  • low amount of calcium in the blood
  • low amount of sodium in the blood
  • low amount of potassium in the blood
  • hemolytic uremic syndrome, a condition that affects the kidney and the blood
  • anemia
  • decreased blood platelets
  • low levels of white blood cells
  • a painful condition that affects the nerves in the legs and arms called peripheral pain, numbness, tingling, or weakness. সহজ বাংলা: স্নায়ুর ক্ষতি/সমস্যা।" data-rx-term="neuropathy" data-rx-definition="Neuropathy means nerve damage or irritation causing pain, numbness, tingling, or weakness. সহজ বাংলা: স্নায়ুর ক্ষতি/সমস্যা।">neuropathy
  • sudden blindness and pain upon moving the eye
  • ototoxicity, damage to the inner ear that affects hearing or balance
  • hearing loss
  • a heart attack
  • a clot in the lung
  • a stroke
  • infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।" data-rx-term="inflammation" data-rx-definition="Inflammation is the body’s response to injury, infection, or irritation, often causing pain, swelling, heat, or redness. সহজ বাংলা: শরীরের প্রদাহ; ব্যথা, ফোলা বা লালভাব হতে পারে।">inflammation of blood vessels in the brain or spinal cord
  • Raynaud’s phenomenon, a condition where blood vessels constrict too much with coldness or stress
  • blood clot in a deep vein of the extremities
  • thrombotic thrombocytopenic purpura, a type of blood disorder
  • decreased kidney function
  • vomiting
  • amount of uric acid in the blood
  •  pregnancy
  • a patient who is producing milk and breastfeeding
  • TPMT poor metabolizer
  • a type of brain disorder called posterior reversible encephalopathy syndrome
  • a clot in the aorta
  • kidney disease with likely reduction in kidney function

Dosage

Strengths: 50 mg; 10 mg; 1 mg/mL

Testicular Cancer

  • 20 mg/m2 by slow IV infusion daily for 5 days per cycle in combination with other approved chemotherapeutic agents

Ovarian Cancer

  • 75 to 100 mg/m2 by slow IV infusion once every 3 to 4 weeks on Day 1

Bladder Cancer

  • 50 to 70 mg/m2 by slow IV infusion once every 3 to 4 weeks; for heavily pretreated patients, an initial dose of 50 mg/m2 by slow IV infusion once every 4 weeks is recommended

FDA Approved Adult Dosing Regimens

  • Advanced testicular cancer: 20 mg.m^2 IV for a single dose on day 1 of a 21 or 28-day cycle; maximum 100 mg/m^2 per cycle.
  • Advanced bladder cancer: 50 to 70 mg.m^2 IV for a single dose on day 1 of a 21 or 28-day cycle; maximum 100 mg/m^2 per cycle.
  • Advanced ovarian cancer: 100 mg.m^2 IV for a single dose on day 1 of a 21 or 28-day cycle; maximum 100 mg/m^2 per cycle.

Cisplatin can be used as monotherapy or as part of a multi-drug regimen. Patients should have proper hydration while monitoring urine output before, during, and for 24 hours following administration.

Renal Dose Adjustments

  • Creatinine clearance between 10 and 50: decrease dose by 25%
  • Creatinine clearance below 10: decrease dose by 50%
  • Hemodialysis: Decrease the dose by 50% with no supplement; administer after dialysis on dialysis days with no supplement
  • Peritoneal dialysis: Decrease the dose by 50% with no supplement

Side Effects

The Most Common

  • nausea
  • vomiting
  • diarrhea
  • hair loss
  • loss in ability to taste food
  • hiccups
  • dry mouth, dark urine, decreased sweating, dry skin, and other signs of dehydration
  • swelling, pain, redness, or burning at the injection site
  • pain, burning, or tingling in the hands or feet
  • muscle cramps
  • difficulty walking
  • feeling of an electric-like shock when you bend your neck forward
  • seizures
  • sudden changes in vision, including color vision
  • loss of vision
  • eye pain
  • chest pain or pressure
  • fever, sore throat, chills, or other signs of infection
  • unusual bleeding or bruising
  • black and tarry stools
  • red blood in stools
  • bloody vomit
  • vomited material that looks like coffee grounds

More Common

  • loss of appetite
  • nausea and vomiting
  • taste disturbances
  • temporary hair loss
  • blurred vision
  • diarrhea
  • difficulty in the ability to distinguish colors
  • difficulty walking
  • hearing difficulties
  • loss of balance
  • loss of reflexes
  • muscle cramps
  • numbness or tingling in fingers or toes
  • ringing in ears
  • severe nausea and vomiting
  • unusual tiredness or weakness
  • walking problems

Rare

  • pain, redness, or swelling at the site of injection
  • seizures
  • signs of a serious allergic reaction (difficulty breathing, wheezing, swelling of the face and throat, increased heart rate, dizziness)
  • signs of bleeding (e.g., unusual bruising or bleeding, pinpoint red spots on the skin, black tarry stools, bloody nose, blood in urine, coughing blood, cuts that don’t stop bleeding)
  • signs of infection (symptoms may include fever or chills, sore throat, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, painful or difficult urination, or listlessness)
  • pain, burning, redness at the injection site,
  • numbness, tingling, coldness or blue discoloration of the hands or feet,
  • pain, redness, swelling of arms or legs,
  • loss of reflexes,
  • loss of balanced,
  • trouble walking,
  • muscle cramps or spasms,
  • weakness,
  • neck or back pain,
  • mouth or tongue sores,
  • joint pain,

Drug Interaction

Pregnancy and Lactation

FDA Pregnancy category D

Pregnancy

There is a possibility of birth defects if either the man or woman is using cisplatin at the time of conception, or if it is taken during pregnancy. This medication should not be used during pregnancy unless the benefits outweigh the risks. Use effective birth control while you are being treated with this medication. If you become pregnant while taking this medication, contact your doctor immediately.

Breast-feeding

This medication passes into breast milk. Women receiving this medication should not breastfeed.

How should this medicine be used?

Cisplatin injection comes as a solution (liquid) to be injected over 6 to 8 hours intravenously (into a vein) by a doctor or nurse in a medical facility. It is usually given once every 3 to 4 weeks.

What special precautions should I follow?

Before taking cisplatin,

  • tell your doctor and pharmacist if you are allergic to cisplatin, carboplatin (Paraplatin), any other medications, or any of the ingredients in cisplatin injection. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention the medications listed in the IMPORTANT WARNING section and any of the following: amphotericin B (Abelcet; AmBisome; Amphotec, Fungizone Intravenous), anticonvulsants such as phenytoin (Dilantin), bumetanide (Bumex), ethacrynic acid (Edecrin), furosemide (Lasix), pyridoxine (Vitamin B-6). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with cisplatin, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
  • tell your doctor if you have kidney disease or hearing problems. Your doctor may not want you to receive cisplatin injection.
  • tell your doctor if you are pregnant, plan to become pregnant, or are breastfeeding. You should not become pregnant or breast-feed while you are receiving cisplatin. If you become pregnant while receiving cisplatin, call your doctor. Cisplatin may harm the fetus.

Before you begin using a medication, be sure to inform your doctor of any medical conditions or allergies you may have, any medications you are taking, whether you are pregnant or breastfeeding, and any other significant facts about your health. These factors may affect how you should use this medication.

Blood clotting: This medication can reduce the number of platelet cells in the blood and increase your risk of bleeding. Tell your doctor immediately if you notice any signs that your blood is not clotting as quickly as usual (e.g., black and tarry stools, blood in the urine, easy bruising, or cuts that won’t stop bleeding). Your doctor will do blood tests regularly to monitor the number of platelets in your blood.

Gout: This medication may cause high levels of uric acid in the blood, making gout more likely to occur. If you have gout or a history of gout, discuss with your doctor how this medication may affect your medical condition, how your medical condition may affect the dosing and effectiveness of this medication, and whether any special monitoring is needed. Report any unusual joint pain or swelling to your doctor as soon as possible.

Hearing impairment: This medication can cause permanent hearing damage and should not be given to anyone with hearing impairment. Your hearing will be monitored closely while you are using this medication.

Infection: In addition to killing cancer cells, this medication can reduce the number of cells that fight infection in the body (white blood cells). If possible, avoid contact with people with contagious infections. Tell your doctor immediately if you notice signs of an infection, such as fever or chills, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, or listlessness. Your doctor will do blood tests regularly to monitor the number of specific types of blood cells in your blood.

Kidney function: Cisplatin can reduce kidney function and cause kidney damage. For this reason, it is very important to drink plenty of fluids right after your treatment. Your doctor may want you to drink extra fluids while taking this medication in order to help you pass more fluid and protect your kidneys. Your doctor will monitor your kidney function closely while you are using this medication. If you have reduced kidney function you should not use this medication.

Nervous system: Cisplatin can cause damage to the nervous system. If you experience symptoms such as loss of taste, tingling in the hands or feet, or balance trouble, tell your doctor as soon as possible. These side effects are often reversible if the medication is stopped early.

References

Doctor visit helper

Prepare before seeing a doctor

A simple rural-patient checklist to help you explain symptoms clearly, ask better questions, and avoid unsafe self-treatment.

Safety note: This is not a prescription or diagnosis. For severe symptoms, pregnancy danger signs, children with serious illness, chest pain, breathing difficulty, stroke-like weakness, or major injury, seek urgent care.

Which doctor may help?

Start with a registered doctor or the nearest qualified health center.

What to tell the doctor

  • Write when the problem started and how it changed.
  • Bring old prescriptions, investigation reports, and current medicines.
  • Write allergies, pregnancy status, diabetes, kidney/liver disease, and major past illnesses.
  • Bring one family member if the patient is weak, elderly, confused, or a child.

Questions to ask

  • What is the most likely cause of my symptoms?
  • Which danger signs mean I should go to hospital quickly?
  • Which tests are necessary now, and which can wait?
  • How should I take medicines safely and what side effects should I watch for?
  • When should I come for follow-up?

Tests to discuss

  • Vital signs: temperature, pulse, blood pressure, oxygen saturation
  • Basic physical examination by a clinician
  • CBC, urine test, blood sugar, or imaging only when clinically needed

Avoid these mistakes

  • Do not use antibiotics, steroid tablets/injections, or strong painkillers without proper medical advice.
  • Do not hide pregnancy, kidney disease, ulcer, allergy, or blood thinner use.
  • Do not delay emergency care when danger signs are present.

Medicine safety and first-aid guide

This section is for patient education only. It does not replace a doctor, pharmacist, or emergency care.

Safe first steps

  • Avoid heavy lifting, sudden bending, and prolonged bed rest.
  • Use comfortable posture and gentle movement as tolerated.
  • Discuss physiotherapy, X-ray, or MRI only when clinically needed.

OTC medicine safety

  • For mild back pain, pain-relief medicine may be discussed with a doctor or pharmacist.
  • Avoid repeated painkiller use if you have kidney disease, stomach ulcer, uncontrolled blood pressure, or are taking blood thinners.

Avoid these mistakes

  • Do not start antibiotics without a proper medical decision.
  • Do not use steroid tablets or injections casually for quick relief.
  • Do not delay emergency care because of home remedies.

Get urgent help if

  • Back pain with leg weakness, numbness around private area, loss of urine/stool control, fever, cancer history, or major injury needs urgent care.
Medicine names, dose, and timing must be decided by a qualified clinician or pharmacist after checking age, pregnancy, allergy, other diseases, and current medicines.

For rural patients and family caregivers

Patient health record and symptom diary

Write your symptoms, medicines already taken, test results, and questions before visiting a doctor. This note stays on your device unless you print or copy it.

Doctor to discuss: Orthopedic / spine specialist, physical medicine doctor, or qualified clinician
Tests to discuss with doctor
  • Neurological examination for leg power, sensation, reflexes, and straight leg raise
  • X-ray only if injury, deformity, long-lasting pain, or doctor suspects bone problem
  • MRI discussion if severe nerve symptoms, weakness, bladder/bowel problem, or persistent symptoms
Questions to ask
  • What is the most likely cause of my symptoms?
  • Which warning signs mean I should go to emergency care?
  • Which tests are really needed now?
  • Which medicines are safe for my age, pregnancy status, allergy, kidney/liver/stomach condition, and current medicines?
  • Is physiotherapy, posture correction, or activity modification needed?

Emergency warning signs such as chest pain, severe breathing difficulty, sudden weakness, confusion, severe dehydration, major injury, or loss of bladder/bowel control need urgent medical care. Do not wait for online information.

Safe pathway to proper treatment

Care roadmap for: Cisplatin – Uses, Dosage, Side Effects, Interaction

Use this simple roadmap to understand the next safe steps. It is educational and does not replace examination by a doctor.

Go to emergency care if you notice:
  • Severe or rapidly worsening symptoms
  • Breathing difficulty, chest pain, fainting, confusion, severe weakness, major injury, or severe dehydration
Doctor / service to discuss: Qualified healthcare provider; specialist depends on symptoms and examination.
  1. Step 1

    Check danger signs first

    If danger signs are present, seek emergency care and do not wait for online information.

  2. Step 2

    Record the symptom story

    Write when symptoms started, severity, medicines already taken, allergies, pregnancy status, and test results.

  3. Step 3

    Visit a qualified clinician

    A doctor, nurse, or qualified healthcare provider can examine you and decide which tests or treatment are needed.

  4. Step 4

    Do only useful tests

    Do tests after clinical assessment. Avoid unnecessary tests, random antibiotics, or repeated medicines without diagnosis.

  5. Step 5

    Follow up and return early if worse

    If symptoms worsen, new warning signs appear, or treatment is not helping, return for review quickly.

Rural patient practical tips
  • Take a written symptom diary and all previous prescriptions/test reports.
  • Do not hide medicines already taken, even herbal or over-the-counter medicines.
  • Ask which warning signs mean urgent referral to hospital.

This roadmap is for education. A real diagnosis and treatment plan requires history, examination, and clinical judgment.

RX Patient Help

Ask a health question safely

Write your symptom story. A health professional or site editor can review it before any answer is prepared. This box is not for emergency care.

Emergency first: Severe chest pain, breathing trouble, unconsciousness, stroke signs, severe injury, heavy bleeding, or rapidly worsening symptoms need urgent local medical care now.

Frequently Asked Questions

Mechanism of action Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations. Cisplatin is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death. Indications For the treatment of metastatic testicular tumors, metastatic ovarian tumors, and advanced bladder cancer. Mantle cell lymphoma that has relapsed (come back) or is refractory (does not respond to treatment). Precursor B lymphoblastic leukemia (a type of acute lymphoblastic leukemia) has relapsed or is refractory. Advanced Ovarian Cancer Ovarian Cancer Metastatic Advanced Bladder cancer Advanced Testicular cancer Metastatic Testicular cancer Use in Cancer Cisplatin is approved to be used alone or with other drugs to treat: Bladder cancer. It is used alone in patients with advanced cancer that cannot be treated with other therapies, such as surgery or radiation therapy. Ovarian cancer has spread to other parts of the body. It is used with other drugs in patients who have already had surgery or radiation therapy. It is used alone in patients whose cancer has not gotten better with standard chemotherapy and who have not received previous cisplatin. Testicular cancer has spread to other parts of the body. It is used with other drugs in patients who have already had surgery or radiation therapy. Cisplatin is also being studied in the treatment of other types of cancer. Contraindications are allergic to cisplatin, any platinum-containing compounds, or any ingredients of the medication have hearing impairment have reduced bone marrow function (e.g. low white cells) have reduced kidney function Severe hypersensitivity to cisplatin or platinum compounds would preclude its administration; cisplatin is contraindicated in patients who have had severe hypersensitivity reactions, and rechallenge is not a recommendation. Cisplatin has been shown to cross the placenta and may cause fetal harm.[rx][rx] Women of reproductive age should use reliable contraception during treatment and up to a year from the final treatment date. Cisplatin is also present in the breast milk of lactating women on a cisplatin regimen.[rx] Breastfeeding is not recommended during treatment.[rx] If hypersensitivity occurs, the provider should discontinue cisplatin immediately.[rx] a bad infection acute leukemia low amount of magnesium in the blood low amount of calcium in the blood low amount of sodium in the blood low amount of potassium in the blood hemolytic uremic syndrome, a condition that affects the kidney and the blood anemia decreased blood platelets low levels of white blood cells a painful condition that affects the nerves in the legs and arms called peripheral neuropathy sudden blindness and pain upon moving the eye ototoxicity, damage to the inner ear that affects hearing or balance hearing loss a heart attack a clot in the lung a stroke inflammation of blood vessels in the brain or spinal cord Raynaud's phenomenon, a condition where blood vessels constrict too much with coldness or stress blood clot in a deep vein of the extremities thrombotic thrombocytopenic purpura, a type of blood disorder decreased kidney function vomiting amount of uric acid in the blood  pregnancy a patient who is producing milk and breastfeeding TPMT poor metabolizer a type of brain disorder called posterior reversible encephalopathy syndrome a clot in the aorta kidney disease with likely reduction in kidney function Dosage Strengths: 50 mg; 10 mg; 1 mg/mL Testicular Cancer 20 mg/m2 by slow IV infusion daily for 5 days per cycle in combination with other approved chemotherapeutic agents Ovarian Cancer 75 to 100 mg/m2 by slow IV infusion once every 3 to 4 weeks on Day 1 Bladder Cancer 50 to 70 mg/m2 by slow IV infusion once every 3 to 4 weeks; for heavily pretreated patients, an initial dose of 50 mg/m2 by slow IV infusion once every 4 weeks is recommended FDA Approved Adult Dosing Regimens Advanced testicular cancer: 20 mg.m^2 IV for a single dose on day 1 of a 21 or 28-day cycle; maximum 100 mg/m^2 per cycle. Advanced bladder cancer: 50 to 70 mg.m^2 IV for a single dose on day 1 of a 21 or 28-day cycle; maximum 100 mg/m^2 per cycle. Advanced ovarian cancer: 100 mg.m^2 IV for a single dose on day 1 of a 21 or 28-day cycle; maximum 100 mg/m^2 per cycle. Cisplatin can be used as monotherapy or as part of a multi-drug regimen. Patients should have proper hydration while monitoring urine output before, during, and for 24 hours following administration. Renal Dose Adjustments Creatinine clearance between 10 and 50: decrease dose by 25% Creatinine clearance below 10: decrease dose by 50% Hemodialysis: Decrease the dose by 50% with no supplement; administer after dialysis on dialysis days with no supplement Peritoneal dialysis: Decrease the dose by 50% with no supplement Side Effects The Most Common nausea vomiting diarrhea hair loss loss in ability to taste food hiccups dry mouth, dark urine, decreased sweating, dry skin, and other signs of dehydration swelling, pain, redness, or burning at the injection site pain, burning, or tingling in the hands or feet muscle cramps difficulty walking feeling of an electric-like shock when you bend your neck forward seizures sudden changes in vision, including color vision loss of vision eye pain chest pain or pressure fever, sore throat, chills, or other signs of infection unusual bleeding or bruising black and tarry stools red blood in stools bloody vomit vomited material that looks like coffee grounds More Common loss of appetite nausea and vomiting taste disturbances temporary hair loss blurred vision diarrhea difficulty in the ability to distinguish colors difficulty walking hearing difficulties loss of balance loss of reflexes muscle cramps numbness or tingling in fingers or toes ringing in ears severe nausea and vomiting unusual tiredness or weakness walking problems Rare pain, redness, or swelling at the site of injection seizures signs of a serious allergic reaction (difficulty breathing, wheezing, swelling of the face and throat, increased heart rate, dizziness) signs of bleeding (e.g., unusual bruising or bleeding, pinpoint red spots on the skin, black tarry stools, bloody nose, blood in urine, coughing blood, cuts that don't stop bleeding) signs of infection (symptoms may include fever or chills, sore throat, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, painful or difficult urination, or listlessness) pain, burning, redness at the injection site, numbness, tingling, coldness or blue discoloration of the hands or feet, pain, redness, swelling of arms or legs, loss of reflexes, loss of balanced, trouble walking, muscle cramps or spasms, weakness, neck or back pain, mouth or tongue sores, joint pain, Drug Interaction DRUG INTERACTION Abacavir Abacavir may decrease the excretion rate of Cisplatin which could result in a higher serum level. Abatacept The risk or severity of adverse effects can be increased when Cisplatin is combined with Abatacept. Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Cisplatin. Acebutolol Cisplatin may increase the bradycardic activities of Acebutolol. Aceclofenac Aceclofenac may decrease the excretion rate of Cisplatin which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Cisplatin. Acetaminophen Acetaminophen may decrease the excretion rate of Cisplatin which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. Acetylcholine The risk or severity of adverse effects can be increased when Cisplatin is combined with Acetylcholine. Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Cisplatin. Acetylsalicylic acid Acetylsalicylic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. Aclidinium Aclidinium may decrease the excretion rate of Cisplatin which could result in a higher serum level. Acrivastine Acrivastine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Acyclovir Acyclovir may decrease the excretion rate of Cisplatin which could result in a higher serum level. Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Cisplatin. Adefovir dipivoxil Adefovir dipivoxil may decrease the excretion rate of Cisplatin which could result in a higher serum level. Adenovirus The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Cisplatin. Albutrepenonacog alfa Albutrepenonacog alfa may decrease the excretion rate of Cisplatin which could result in a higher serum level. Alclofenac Alclofenac may decrease the excretion rate of Cisplatin which could result in a higher serum level. Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Cisplatin. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Cisplatin. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Cisplatin. Alendronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Alendronic acid. Allogeneic processed The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Cisplatin. Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Cisplatin. Almasilate Almasilate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Almotriptan Almotriptan may decrease the excretion rate of Cisplatin which could result in a higher serum level. Alogliptin Alogliptin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Alprazolam Alprazolam may decrease the excretion rate of Cisplatin which could result in a higher serum level. Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Cisplatin. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Cisplatin. Amantadine The serum concentration of Cisplatin can be increased when it is combined with Amantadine. Amifampridine The risk or severity of adverse effects can be increased when Cisplatin is combined with Amifampridine. Amikacin Amikacin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Amiloride The serum concentration of Cisplatin can be increased when it is combined with Amiloride. Aminohippuric acid The serum concentration of Cisplatin can be increased when it is combined with Aminohippuric acid. Aminophenazone Aminophenazone may decrease the excretion rate of Cisplatin which could result in a higher serum level. Amiodarone The serum concentration of Cisplatin can be increased when it is combined with Amiodarone. Amitriptyline Amitriptyline may decrease the excretion rate of Cisplatin which could result in a higher serum level. Ammonium chloride Ammonium chloride may decrease the excretion rate of Cisplatin which could result in a higher serum level. Amobarbital The therapeutic efficacy of Amobarbital can be decreased when used in combination with Cisplatin. Amoxapine The therapeutic efficacy of Amoxapine can be decreased when used in combination with Cisplatin. Amoxicillin Amoxicillin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Amphetamine Amphetamine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Amphotericin B Amphotericin B may decrease the excretion rate of Cisplatin which could result in a higher serum level. Ampicillin Ampicillin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Amrinone Amrinone may decrease the excretion rate of Cisplatin which could result in a higher serum level. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Cisplatin. Anagrelide The risk or severity of bleeding can be increased when Anagrelide is combined with Cisplatin. Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Cisplatin. Anastrozole The risk or severity of cardiotoxicity can be increased when Cisplatin is combined with Anastrozole. Ancestim Ancestim may decrease the excretion rate of Cisplatin which could result in a higher serum level. Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Cisplatin. Anifrolumab The risk or severity of adverse effects can be increased when Cisplatin is combined with Anifrolumab. Belatacept The risk or severity of adverse effects can be increased when Cisplatin is combined with Belatacept. Belimumab The risk or severity of adverse effects can be increased when Cisplatin is combined with Belimumab. Belinostat The risk or severity of adverse effects can be increased when Cisplatin is combined with Belinostat. Belladonna The therapeutic efficacy of Belladonna can be decreased when used in combination with Cisplatin. Belumosudil The risk or severity of adverse effects can be increased when Cisplatin is combined with Belumosudil. Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Cisplatin. Bendamustine The risk or severity of adverse effects can be increased when Cisplatin is combined with Bendamustine. Bendroflumethiazide Bendroflumethiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. Benorilate Benorilate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Benoxaprofen Benoxaprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level. Benserazide Benserazide may decrease the excretion rate of Cisplatin which could result in a higher serum level. Benzatropine Benzatropine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Benznidazole Benznidazole may decrease the excretion rate of Cisplatin which could result in a higher serum level. Benzocaine The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Benzocaine. Benzonatate Cisplatin may increase the neuromuscular blocking activities of Benzonatate. Benzphetamine The metabolism of Benzphetamine can be decreased when combined with Cisplatin. Benzthiazide Benzthiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. Benzydamine Benzydamine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Benzyl alcohol. Bepotastine Bepotastine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Betamethasone The therapeutic efficacy of Cisplatin can be decreased when used in combination with Betamethasone. Betamethasone phosphate The therapeutic efficacy of Cisplatin can be decreased when used in combination with Betamethasone phosphate. Betaxolol Cisplatin may increase the bradycardic activities of Betaxolol. Bethanechol The risk or severity of adverse effects can be increased when Cisplatin is combined with Bethanechol. Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with Cisplatin. Bevacizumab The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Cisplatin. Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Cisplatin. Bicisate Bicisate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Bimekizumab The risk or severity of adverse effects can be increased when Cisplatin is combined with Bimekizumab. Biperiden The therapeutic efficacy of Biperiden can be decreased when used in combination with Cisplatin. Bismuth subgallate Bismuth subgallate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Bisoprolol Bisoprolol may decrease the excretion rate of Cisplatin which could result in a higher serum level. Bisoxatin Bisoxatin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Cisplatin. Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Cisplatin. Blinatumomab The risk or severity of adverse effects can be increased when Cisplatin is combined with Blinatumomab. Bordetella pertussis The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Cisplatin. Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Cisplatin. Bosutinib The risk or severity of adverse effects can be increased when Cisplatin is combined with Bosutinib. Brentuximab vedotin The risk or severity of adverse effects can be increased when Cisplatin is combined with Brentuximab vedotin. Brivaracetam Brivaracetam may decrease the excretion rate of Cisplatin which could result in a higher serum level. Brodalumab The risk or severity of adverse effects can be increased when Cisplatin is combined with Brodalumab. Bromazepam Bromazepam may decrease the excretion rate of Cisplatin which could result in a higher serum level. Bromotheophylline Bromotheophylline may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. Brompheniramine The metabolism of Brompheniramine can be decreased when combined with Cisplatin. Buclizine The therapeutic efficacy of Buclizine can be decreased when used in combination with Cisplatin. Budesonide The therapeutic efficacy of Cisplatin can be decreased when used in combination with Budesonide. Bumadizone Bumadizone may decrease the excretion rate of Cisplatin which could result in a higher serum level. Bumetanide The risk or severity of ototoxicity and nephrotoxicity can be increased when Bumetanide is combined with Cisplatin. Bupivacaine The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Bupivacaine. Bupropion The excretion of Cisplatin can be decreased when combined with Bupropion. Buspirone Buspirone may decrease the excretion rate of Cisplatin which could result in a higher serum level. Busulfan The risk or severity of adverse effects can be increased when Cisplatin is combined with Busulfan. Butabarbital Butabarbital may decrease the excretion rate of Cisplatin which could result in a higher serum level. Butacaine The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Butacaine. Butalbital The therapeutic efficacy of Butalbital can be decreased when used in combination with Cisplatin. Butamben The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Butamben. Butobarbital The therapeutic efficacy of Butobarbital can be decreased when used in combination with Cisplatin. Butylscopolamine The therapeutic efficacy of Butylscopolamine can be decreased when used in combination with Cisplatin. Cabazitaxel The risk or severity of adverse effects can be increased when Cisplatin is combined with Cabazitaxel. Canagliflozin Canagliflozin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Canakinumab The risk or severity of adverse effects can be increased when Cisplatin is combined with Canakinumab. Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Cisplatin. Canrenoic acid Canrenoic acid may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. Capecitabine The risk or severity of adverse effects can be increased when Cisplatin is combined with Capecitabine. Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Cisplatin. Capreomycin Capreomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Capsaicin The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Capsaicin. Carbamazepine The risk or severity of adverse effects can be increased when Cisplatin is combined with Carbamazepine. Carbamoylcholine The risk or severity of adverse effects can be increased when Cisplatin is combined with Carbamoylcholine. Carbidopa Carbidopa may decrease the excretion rate of Cisplatin which could result in a higher serum level. Carboplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Carboplatin. Carfilzomib The risk or severity of adverse effects can be increased when Cisplatin is combined with Carfilzomib. Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Cisplatin. Carprofen Carprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level. Carvedilol Cisplatin may increase the bradycardic activities of Carvedilol. Cefaclor Cefaclor may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cefadroxil Cefadroxil may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cefalotin Cefalotin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cefamandole Cefamandole may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cefapirin Cefapirin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cefazolin Cefazolin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cefdinir Cefdinir may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cefditoren Cefditoren may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cefepime Cefepime may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cefmenoxime Cefmenoxime may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cefmetazole Cefmetazole may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cefonicid Cefonicid may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cefoperazone Cefoperazone may decrease the excretion rate of Cisplatin which could result in a higher serum level. Ceforanide Ceforanide may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cefotaxime Cefotaxime may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cefotetan Cefotetan may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cefotiam Cefotiam may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cefoxitin Cefoxitin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cefpiramide Cefpiramide may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cefpirome Cefpirome may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cefpodoxime Cefpodoxime may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cefprozil Cefprozil may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cefradine Cefradine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Ceftazidime Ceftazidime may decrease the excretion rate of Cisplatin which could result in a higher serum level. Ceftibuten Ceftibuten may decrease the excretion rate of Cisplatin which could result in a higher serum level. Ceftizoxime Ceftizoxime may decrease the excretion rate of Cisplatin which could result in a higher serum level. Ceftobiprole Ceftobiprole may decrease the excretion rate of Cisplatin which could result in a higher serum level. Ceftolozane Ceftolozane may decrease the excretion rate of Cisplatin which could result in a higher serum level. Ceftriaxone Ceftriaxone may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cefuroxime Cefuroxime may decrease the excretion rate of Cisplatin which could result in a higher serum level. Celecoxib Celecoxib may decrease the excretion rate of Cisplatin which could result in a higher serum level. Celiprolol Cisplatin may increase the bradycardic activities of Celiprolol. Cenobamate The metabolism of Cenobamate can be decreased when combined with Cisplatin. Cephalexin Cephalexin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cephaloglycin Cephaloglycin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Certolizumab pegol The risk or severity of adverse effects can be increased when Cisplatin is combined with Certolizumab pegol. Cetirizine Cetirizine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cevimeline Cevimeline may decrease the excretion rate of Cisplatin which could result in a higher serum level. Chloral hydrate Chloral hydrate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Cisplatin. Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Cisplatin. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Chloroprocaine. Chloroquine Chloroquine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Chlorothiazide Chlorothiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. Chloroxylenol Chloroxylenol may decrease the excretion rate of Cisplatin which could result in a higher serum level. Chlorpheniramine The serum concentration of Cisplatin can be increased when it is combined with Chlorpheniramine. Chlorpromazine Chlorpromazine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Chlorpropamide Chlorpropamide may decrease the excretion rate of Cisplatin which could result in a higher serum level. Chlorprothixene The therapeutic efficacy of Chlorprothixene can be decreased when used in combination with Cisplatin. Chlorthalidone Chlorthalidone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. Chlorzoxazone Chlorzoxazone may decrease the excretion rate of Cisplatin which could result in a higher serum level. Choline The serum concentration of Cisplatin can be increased when it is combined with Choline. Choline C 11 Choline C 11 may decrease the excretion rate of Cisplatin which could result in a higher serum level. Choline magnesium Choline magnesium trisalicylate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Choline salicylate The serum concentration of Cisplatin can be increased when it is combined with Choline salicylate. Chondroitin sulfate Chondroitin sulfate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Chromic chloride Chromic chloride may decrease the excretion rate of Cisplatin which could result in a higher serum level. Chromic nitrate Chromic nitrate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Chromium Chromium may decrease the excretion rate of Cisplatin which could result in a higher serum level. Chromium gluconate Chromium gluconate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Chromium nicotinate Chromium nicotinate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Chromous sulfate Chromous sulfate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Ciclesonide The therapeutic efficacy of Cisplatin can be decreased when used in combination with Ciclesonide. Cidofovir Cidofovir may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cilostazol Cilostazol may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cimetidine The serum concentration of Cisplatin can be increased when it is combined with Cimetidine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Cinchocaine. Cinnarizine The metabolism of Cinnarizine can be decreased when combined with Cisplatin. Ciprofloxacin Ciprofloxacin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Cisapride The metabolism of Cisapride can be decreased when combined with Cisplatin. Cisatracurium The therapeutic efficacy of Cisatracurium can be decreased when used in combination with Cisplatin. Cladribine The risk or severity of adverse effects can be increased when Cladribine is combined with Cisplatin. Clevidipine Clevidipine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Clidinium The therapeutic efficacy of Clidinium can be decreased when used in combination with Cisplatin. Clobazam Clobazam may decrease the excretion rate of Cisplatin which could result in a higher serum level. Clobetasol propionate The therapeutic efficacy of Cisplatin can be decreased when used in combination with Clobetasol propionate. Clodronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Clodronic acid. Clofarabine The risk or severity of adverse effects can be increased when Cisplatin is combined with Clofarabine. Clomipramine Clomipramine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Clonazepam Clonazepam may decrease the excretion rate of Cisplatin which could result in a higher serum level. Clopidogrel The serum concentration of Cisplatin can be increased when it is combined with Clopidogrel. Clorazepic acid Clorazepic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. Clostridium The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cisplatin. Clotiazepam The metabolism of Clotiazepam can be decreased when combined with Cisplatin. Clove oil Clove oil may decrease the excretion rate of Cisplatin which could result in a higher serum level. Clozapine The risk or severity of neutropenia can be increased when Cisplatin is combined with Clozapine. Cocaine The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Cocaine. Colchicine Colchicine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Colistimethate Colistimethate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Colistin Cisplatin may decrease the excretion rate of Colistin which could result in a higher serum level. Conivaptan Conivaptan may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. Conjugated Conjugated estrogens may decrease the excretion rate of Cisplatin which could result in a higher serum level. Corifollitropin alfa Corifollitropin alfa may decrease the excretion rate of Cisplatin which could result in a higher serum level. Corticotropin The therapeutic efficacy of Cisplatin can be decreased when used in combination with Corticotropin. Cortisone acetate The therapeutic efficacy of Cisplatin can be decreased when used in combination with Cortisone acetate. Corynebacterium The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Cisplatin. Crizotinib The serum concentration of Cisplatin can be increased when it is combined with Crizotinib. Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Cisplatin. Cyclopenthiazide Cyclopenthiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. Cyclophosphamide The metabolism of Cyclophosphamide can be decreased when combined with Cisplatin. Cyclosporine Cisplatin may increase the immunosuppressive activities of Cyclosporine. Cyclothiazide Cyclothiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. Cycrimine The therapeutic efficacy of Cycrimine can be decreased when used in combination with Cisplatin. Cyproheptadine The therapeutic efficacy of Cyproheptadine can be decreased when used in combination with Cisplatin. Cytarabine The risk or severity of adverse effects can be increased when Cisplatin is combined with Cytarabine. Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Cisplatin. Dabigatran etexilate Dabigatran etexilate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Dabrafenib The serum concentration of Cisplatin can be increased when it is combined with Dabrafenib. Dacarbazine The risk or severity of adverse effects can be increased when Cisplatin is combined with Dacarbazine. Dactinomycin The risk or severity of adverse effects can be increased when Cisplatin is combined with Dactinomycin. Dalfampridine The serum concentration of Dalfampridine can be increased when it is combined with Cisplatin. Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Cisplatin. Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Cisplatin. Dapagliflozin Dapagliflozin may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. Daptomycin Daptomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Cisplatin. Darifenacin The therapeutic efficacy of Darifenacin can be decreased when used in combination with Cisplatin. Dasatinib The risk or severity of adverse effects can be increased when Cisplatin is combined with Dasatinib. Daunorubicin The risk or severity of adverse effects can be increased when Cisplatin is combined with Daunorubicin. Decitabine The risk or severity of adverse effects can be increased when Cisplatin is combined with Decitabine. Deferiprone Deferiprone may decrease the excretion rate of Cisplatin which could result in a higher serum level. Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Cisplatin. Deflazacort The therapeutic efficacy of Cisplatin can be decreased when used in combination with Deflazacort. Delafloxacin Delafloxacin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Cisplatin. Desipramine The serum concentration of Cisplatin can be increased when it is combined with Desipramine. Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Cisplatin. Deslanoside Deslanoside may decrease the cardiotoxic activities of Cisplatin. Desloratadine The therapeutic efficacy of Desloratadine can be decreased when used in combination with Cisplatin. Desmopressin Desmopressin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Desoximetasone The therapeutic efficacy of Cisplatin can be decreased when used in combination with Desoximetasone. Desvenlafaxine Desvenlafaxine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Deucravacitinib The risk or severity of adverse effects can be increased when Cisplatin is combined with Deucravacitinib. Deutetrabenazine Deutetrabenazine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Dexamethasone The therapeutic efficacy of Cisplatin can be decreased when used in combination with Dexamethasone. Dexamethasone acetate The therapeutic efficacy of Cisplatin can be decreased when used in combination with Dexamethasone acetate. Dexchlorpheniramine The serum concentration of Cisplatin can be increased when it is combined with Dexchlorpheniramine maleate. Dexibuprofen Dexibuprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level. Dexketoprofen Dexketoprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level. Dexmedetomidine Dexmedetomidine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Dexpanthenol Dexpanthenol may decrease the excretion rate of Cisplatin which could result in a higher serum level. Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Cisplatin. Dextran Dextran may decrease the excretion rate of Cisplatin which could result in a higher serum level. Dextromethorphan The therapeutic efficacy of Dextromethorphan can be decreased when used in combination with Cisplatin. Diatrizoate Diatrizoate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Diazepam Diazepam may decrease the excretion rate of Cisplatin which could result in a higher serum level. Dichlorobenzyl alcohol Dichlorobenzyl alcohol may decrease the excretion rate of Cisplatin which could result in a higher serum level. Diclofenac Diclofenac may decrease the excretion rate of Cisplatin which could result in a higher serum level. Diclofenamide Diclofenamide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Cisplatin. Dicyclomine Dicyclomine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Didanosine Didanosine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Dienogest Dienogest may decrease the excretion rate of Cisplatin which could result in a higher serum level. Diflunisal Diflunisal may decrease the excretion rate of Cisplatin which could result in a higher serum level. Difluocortolone The therapeutic efficacy of Cisplatin can be decreased when used in combination with Difluocortolone. Digitoxin Digitoxin may decrease the cardiotoxic activities of Cisplatin. Digoxin Cisplatin may decrease the excretion rate of Digoxin which could result in a higher serum level. Dihydrostreptomycin Dihydrostreptomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Dimercaprol Dimercaprol may decrease the excretion rate of Cisplatin which could result in a higher serum level. Dimethyl fumarate The risk or severity of adverse effects can be increased when Cisplatin is combined with Dimethyl fumarate. Dimethyl sulfoxide Dimethyl sulfoxide may decrease the excretion rate of Cisplatin which could result in a higher serum level. Dimetindene The therapeutic efficacy of Dimetindene can be decreased when used in combination with Cisplatin. Dinoprostone The serum concentration of Cisplatin can be increased when it is combined with Dinoprostone. Dinutuximab The risk or severity of adverse effects can be increased when Cisplatin is combined with Dinutuximab. Diphemanil The therapeutic efficacy of Diphemanil can be decreased when used in combination with Cisplatin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Diphenhydramine. Diphenidol The therapeutic efficacy of Diphenidol can be decreased when used in combination with Cisplatin. Dipyridamole The therapeutic efficacy of Cisplatin can be decreased when used in combination with Dipyridamole. Diroximel fumarate The risk or severity of adverse effects can be increased when Cisplatin is combined with Diroximel fumarate. Disopyramide The serum concentration of Cisplatin can be increased when it is combined with Disopyramide. DL-Methylephedrine DL-Methylephedrine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Dobutamine Dobutamine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Docetaxel The risk or severity of adverse effects can be increased when Cisplatin is combined with Docetaxel. Dofetilide The serum concentration of Dofetilide can be increased when it is combined with Cisplatin. Dolutegravir The serum concentration of Cisplatin can be increased when it is combined with Dolutegravir. Domperidone The metabolism of Domperidone can be decreased when combined with Cisplatin. Dopamine The serum concentration of Cisplatin can be increased when it is combined with Dopamine. Doripenem Doripenem may decrease the excretion rate of Cisplatin which could result in a higher serum level. Dosulepin The metabolism of Dosulepin can be decreased when combined with Cisplatin. Doxacurium Doxacurium may decrease the excretion rate of Cisplatin which could result in a higher serum level. Doxepin Doxepin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Doxorubicin The risk or severity of adverse effects can be increased when Cisplatin is combined with Doxorubicin. Doxycycline Doxycycline may decrease the excretion rate of Cisplatin which could result in a higher serum level. Doxylamine The therapeutic efficacy of Doxylamine can be decreased when used in combination with Cisplatin. Dronedarone The serum concentration of Cisplatin can be increased when it is combined with Dronedarone. Drospirenone Drospirenone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Cisplatin. Droxidopa Droxidopa may decrease the excretion rate of Cisplatin which could result in a higher serum level. Duloxetine Duloxetine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Dyclonine The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Dyclonine. Dyphylline Dyphylline may decrease the excretion rate of Cisplatin which could result in a higher serum level. Ebola Zaire vaccine The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Cisplatin. Eculizumab The risk or severity of adverse effects can be increased when Cisplatin is combined with Eculizumab. Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Cisplatin. Edoxaban Edoxaban may decrease the excretion rate of Cisplatin which could result in a higher serum level. Edrophonium Edrophonium may decrease the excretion rate of Cisplatin which could result in a higher serum level. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Cisplatin. Efavirenz The metabolism of Efavirenz can be decreased when combined with Cisplatin. Emapalumab The risk or severity of adverse effects can be increased when Cisplatin is combined with Emapalumab. Enalaprilat Enalaprilat may decrease the excretion rate of Cisplatin which could result in a higher serum level. Enasidenib The metabolism of Enasidenib can be decreased when combined with Cisplatin. Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Cisplatin. Enzalutamide Enzalutamide may decrease the excretion rate of Cisplatin which could result in a higher serum level. Ephedrine Cisplatin may increase the neuromuscular blocking activities of Ephedrine. Epinastine The metabolism of Epinastine can be decreased when combined with Cisplatin. Epinephrine The serum concentration of Cisplatin can be increased when it is combined with Epinephrine. Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Cisplatin. Eplerenone Eplerenone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. Epoprostenol Epoprostenol may decrease the excretion rate of Cisplatin which could result in a higher serum level. Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Cisplatin. Erdafitinib The serum concentration of Cisplatin can be increased when it is combined with Erdafitinib. Eribulin The risk or severity of adverse effects can be increased when Cisplatin is combined with Eribulin. Ertapenem Ertapenem may decrease the excretion rate of Cisplatin which could result in a higher serum level. Ertugliflozin Ertugliflozin may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Cisplatin. Escitalopram The therapeutic efficacy of Escitalopram can be decreased when used in combination with Cisplatin. Esketamine The metabolism of Esketamine can be decreased when combined with Cisplatin. Esmolol Cisplatin may increase the bradycardic activities of Esmolol. Estazolam Estazolam may decrease the excretion rate of Cisplatin which could result in a higher serum level. Estradiol The serum concentration of Cisplatin can be increased when it is combined with Estradiol. Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Cisplatin. Ethambutol Ethambutol may decrease the excretion rate of Cisplatin which could result in a higher serum level. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Etidocaine. Etidronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Etidronic acid. Etodolac Etodolac may decrease the excretion rate of Cisplatin which could result in a higher serum level. Etomidate Etomidate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Etonogestrel Etonogestrel may decrease the excretion rate of Cisplatin which could result in a higher serum level. Etoposide The risk or severity of adverse effects can be increased when Cisplatin is combined with Etoposide. Etoricoxib Etoricoxib may decrease the excretion rate of Cisplatin which could result in a higher serum level. Eucalyptus oil Eucalyptus oil may decrease the excretion rate of Cisplatin which could result in a higher serum level. Everolimus The risk or severity of adverse effects can be increased when Cisplatin is combined with Everolimus. Ezogabine Ezogabine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Famotidine The serum concentration of Cisplatin can be increased when it is combined with Famotidine. Fenbufen Fenbufen may decrease the excretion rate of Cisplatin which could result in a higher serum level. Fenfluramine The metabolism of Fenfluramine can be decreased when combined with Cisplatin. Fenofibrate Fenofibrate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Fenofibric acid Fenofibric acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. Fenoldopam Fenoldopam may decrease the excretion rate of Cisplatin which could result in a higher serum level. Fenoprofen Fenoprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level. Fenoterol The therapeutic efficacy of Fenoterol can be decreased when used in combination with Cisplatin. Fentanyl Fentanyl may decrease the excretion rate of Cisplatin which could result in a higher serum level. Fesoterodine Fesoterodine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Fexinidazole The serum concentration of Cisplatin can be increased when it is combined with Fexinidazole. Filgotinib The risk or severity of adverse effects can be increased when Cisplatin is combined with Filgotinib. Finerenone Finerenone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. Fingolimod Cisplatin may increase the immunosuppressive activities of Fingolimod. Flavoxate Flavoxate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Floctafenine Floctafenine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Florbetaben (18F) Florbetaben (18F) may decrease the excretion rate of Cisplatin which could result in a higher serum level. Florbetapir (18F) Florbetapir (18F) may decrease the excretion rate of Cisplatin which could result in a higher serum level. Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Cisplatin. Fluconazole Fluconazole may decrease the excretion rate of Cisplatin which could result in a higher serum level. Flucytosine The risk or severity of adverse effects can be increased when Cisplatin is combined with Flucytosine. Fludarabine The risk or severity of adverse effects can be increased when Cisplatin is combined with Fludarabine. Fludeoxyglucose (18F) Fludeoxyglucose (18F) may decrease the excretion rate of Cisplatin which could result in a higher serum level. Fludrocortisone The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fludrocortisone. Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Cisplatin. Flumazenil Flumazenil may decrease the excretion rate of Cisplatin which could result in a higher serum level. Flumethasone The therapeutic efficacy of Cisplatin can be decreased when used in combination with Flumethasone. Flunisolide The therapeutic efficacy of Cisplatin can be decreased when used in combination with Flunisolide. Flunitrazepam The metabolism of Flunitrazepam can be decreased when combined with Cisplatin. Fluocinolone acetonide The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluocinolone acetonide. Fluocinonide The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluocinonide. Fluocortolone The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluocortolone. Fluorometholone The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluorometholone. Fluorouracil The risk or severity of adverse effects can be increased when Cisplatin is combined with Fluorouracil. Fluoxetine The therapeutic efficacy of Fluoxetine can be decreased when used in combination with Cisplatin. Flupentixol The risk or severity of myelosuppression can be increased when Flupentixol is combined with Cisplatin. Fluprednisolone The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluprednisolone. Flurazepam The serum concentration of Cisplatin can be increased when it is combined with Flurazepam. Flurbiprofen Flurbiprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level. Flutamide Flutamide may decrease the excretion rate of Cisplatin which could result in a higher serum level. Fluticasone The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluticasone. Fluticasone furoate The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluticasone furoate. Fluticasone The therapeutic efficacy of Cisplatin can be decreased when used in combination with Fluticasone propionate. Fluvoxamine Fluvoxamine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Folic acid Folic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. Fomepizole Fomepizole may decrease the excretion rate of Cisplatin which could result in a higher serum level. Fondaparinux Fondaparinux may decrease the excretion rate of Cisplatin which could result in a higher serum level. Formestane Formestane may decrease the excretion rate of Cisplatin which could result in a higher serum level. Foscarnet The risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Foscarnet. Fosfomycin Fosfomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Fosinopril Fosinopril may decrease the excretion rate of Cisplatin which could result in a higher serum level. Fosphenytoin Cisplatin can cause a decrease in the absorption of Fosphenytoin resulting in a reduced serum concentration and potentially a decrease in efficacy. Framycetin Framycetin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Furosemide Furosemide may increase the nephrotoxic and ototoxic activities of Cisplatin. Gabapentin enacarbil Gabapentin enacarbil may decrease the excretion rate of Cisplatin which could result in a higher serum level. Gadobenic acid Gadobenic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. Gadodiamide Gadodiamide may decrease the excretion rate of Cisplatin which could result in a higher serum level. Gadofosveset trisodium Gadofosveset trisodium may decrease the excretion rate of Cisplatin which could result in a higher serum level. Gadopentetic acid Gadopentetic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. Gadoteric acid Gadoteric acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. Gadoteridol Gadoteridol may decrease the excretion rate of Cisplatin which could result in a higher serum level. Gallamine The therapeutic efficacy of Gallamine triethiodide can be decreased when used in combination with Cisplatin. Gallium nitrate The risk or severity of adverse effects can be increased when Cisplatin is combined with Gallium nitrate. Ganciclovir Ganciclovir may decrease the excretion rate of Cisplatin which could result in a higher serum level. Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Cisplatin. Gemfibrozil Gemfibrozil may decrease the excretion rate of Cisplatin which could result in a higher serum level. Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Cisplatin. Gentamicin The serum concentration of Gentamicin can be increased when it is combined with Cisplatin. Gimeracil Gimeracil may decrease the excretion rate of Cisplatin which could result in a higher serum level. Givosiran Givosiran may decrease the excretion rate of Cisplatin which could result in a higher serum level. Glatiramer The risk or severity of adverse effects can be increased when Cisplatin is combined with Glatiramer. Glipizide Glipizide may decrease the excretion rate of Cisplatin which could result in a higher serum level. Glycerol phenylbutyrate Glycerol phenylbutyrate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Glycopyrronium The therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Cisplatin. Golimumab The risk or severity of adverse effects can be increased when Cisplatin is combined with Golimumab. Golodirsen Golodirsen may decrease the excretion rate of Cisplatin which could result in a higher serum level. Goserelin Goserelin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Grepafloxacin The serum concentration of Cisplatin can be increased when it is combined with Grepafloxacin. Guanethidine Guanethidine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Haloperidol Haloperidol may decrease the excretion rate of Cisplatin which could result in a higher serum level. Halothane The metabolism of Halothane can be decreased when combined with Cisplatin. Heparin The risk or severity of bleeding can be increased when Heparin is combined with Cisplatin. Hepatitis A Vaccine The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Cisplatin. Hepatitis B Vaccine The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Cisplatin. Hexafluronium The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Cisplatin. Hexocyclium The therapeutic efficacy of Hexocyclium can be decreased when used in combination with Cisplatin. Histamine The serum concentration of Cisplatin can be increased when it is combined with Histamine. Homatropine The therapeutic efficacy of Homatropine methylbromide can be decreased when used in combination with Cisplatin. Human adenovirus The risk or severity of infection can be increased when Human adenovirus e serotype 4 strain cl-68578 antigen is combined with Cisplatin. Hydralazine Hydralazine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Hydrochlorothiazide Hydrochlorothiazide may decrease the excretion rate of Cisplatin which could result in a higher serum level. Hydrocodone The metabolism of Hydrocodone can be decreased when combined with Cisplatin. Hydrocortisone The therapeutic efficacy of Cisplatin can be decreased when used in combination with Hydrocortisone. Hydrocortisone acetate The therapeutic efficacy of Cisplatin can be decreased when used in combination with Hydrocortisone acetate. Hydrocortisone butyrate The therapeutic efficacy of Cisplatin can be decreased when used in combination with Hydrocortisone butyrate. Hydrocortisone cypionate The therapeutic efficacy of Cisplatin can be decreased when used in combination with Hydrocortisone cypionate. Hydrocortisone succinate The therapeutic efficacy of Cisplatin can be decreased when used in combination with Hydrocortisone succinate. Hydroflumethiazide Hydroflumethiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. Hydromorphone Hydromorphone may decrease the excretion rate of Cisplatin which could result in a higher serum level. Hydroxocobalamin Hydroxocobalamin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Hydroxychloroquine The risk or severity of adverse effects can be increased when Cisplatin is combined with Hydroxychloroquine. Hydroxyethyl Starch Hydroxyethyl Starch may decrease the excretion rate of Cisplatin which could result in a higher serum level. Hydroxyurea The risk or severity of adverse effects can be increased when Cisplatin is combined with Hydroxyurea. Hyoscyamine The therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Cisplatin. Ibandronate The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Ibandronate. Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Cisplatin. Ibrutinib The risk or severity of adverse effects can be increased when Cisplatin is combined with Ibrutinib. Ibuprofen Ibuprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level. Ibutilide Ibutilide may decrease the excretion rate of Cisplatin which could result in a higher serum level. Icatibant Icatibant may decrease the excretion rate of Cisplatin which could result in a higher serum level. Icosapent Icosapent may decrease the excretion rate of Cisplatin which could result in a higher serum level. Icosapent ethyl The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Cisplatin. Idarubicin The risk or severity of adverse effects can be increased when Cisplatin is combined with Idarubicin. Idarucizumab Idarucizumab may decrease the excretion rate of Cisplatin which could result in a higher serum level. Idebenone Idebenone may decrease the excretion rate of Cisplatin which could result in a higher serum level. Idelalisib The risk or severity of adverse effects can be increased when Cisplatin is combined with Idelalisib. Ifosfamide The metabolism of Ifosfamide can be decreased when combined with Cisplatin. Iloprost The risk or severity of bleeding can be increased when Iloprost is combined with Cisplatin. Imatinib The risk or severity of adverse effects can be increased when Cisplatin is combined with Imatinib. Imipramine The serum concentration of Cisplatin can be increased when it is combined with Imipramine. Indapamide Indapamide may decrease the excretion rate of Cisplatin which could result in a higher serum level. Indigotindisulfonic acid Indigotindisulfonic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Cisplatin. Inebilizumab The risk or severity of infection can be increased when Cisplatin is combined with Inebilizumab. Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Cisplatin. Ketoprofen Ketoprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level. Ketorolac Ketorolac may decrease the excretion rate of Cisplatin which could result in a higher serum level. Labetalol Labetalol may decrease the excretion rate of Cisplatin which could result in a higher serum level. Lamivudine Lamivudine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Lamotrigine The serum concentration of Cisplatin can be increased when it is combined with Lamotrigine. Latamoxef Latamoxef may decrease the excretion rate of Cisplatin which could result in a higher serum level. Ledipasvir Ledipasvir may decrease the excretion rate of Cisplatin which could result in a higher serum level. Leflunomide The risk or severity of adverse effects can be increased when Cisplatin is combined with Leflunomide. Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Cisplatin. Lenvatinib The serum concentration of Cisplatin can be increased when it is combined with Lenvatinib. Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Cisplatin. Lesinurad Lesinurad may decrease the excretion rate of Cisplatin which could result in a higher serum level. Leuprolide Leuprolide may decrease the excretion rate of Cisplatin which could result in a higher serum level. Levacetylmethadol The therapeutic efficacy of Levacetylmethadol can be decreased when used in combination with Cisplatin. Levobetaxolol Cisplatin may increase the bradycardic activities of Levobetaxolol. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Levobupivacaine. Levocarnitine Levocarnitine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Levocetirizine Levocetirizine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Levofloxacin Levofloxacin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Levoketoconazole The serum concentration of Cisplatin can be increased when it is combined with Levoketoconazole. Levomilnacipran Levomilnacipran may decrease the excretion rate of Cisplatin which could result in a higher serum level. Levosalbutamol Levosalbutamol may decrease the excretion rate of Cisplatin which could result in a higher serum level. Lidocaine The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Lidocaine. Linagliptin The serum concentration of Cisplatin can be increased when it is combined with Linagliptin. Linezolid The risk or severity of adverse effects can be increased when Cisplatin is combined with Linezolid. Liothyronine Liothyronine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Lipegfilgrastim Cisplatin may increase the myelosuppressive activities of Lipegfilgrastim. Lipoic acid The risk or severity of cytotoxicity can be decreased when Lipoic acid is combined with Cisplatin. Lisinopril Lisinopril may decrease the excretion rate of Cisplatin which could result in a higher serum level. Lithium carbonate Cisplatin may decrease the excretion rate of Lithium carbonate which could result in a higher serum level. Lithium citrate Lithium citrate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Lixisenatide Lixisenatide may decrease the excretion rate of Cisplatin which could result in a higher serum level. Lofexidine Lofexidine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Lomustine The risk or severity of adverse effects can be increased when Cisplatin is combined with Lomustine. Lopinavir The serum concentration of Cisplatin can be increased when it is combined with Lopinavir. Loracarbef Loracarbef may decrease the excretion rate of Cisplatin which could result in a higher serum level. Lorazepam Lorazepam may decrease the excretion rate of Cisplatin which could result in a higher serum level. Lorcaserin Lorcaserin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Lornoxicam Lornoxicam may decrease the excretion rate of Cisplatin which could result in a higher serum level. Lorpiprazole Lorpiprazole may decrease the excretion rate of Cisplatin which could result in a higher serum level. Loxoprofen Loxoprofen may decrease the excretion rate of Cisplatin which could result in a higher serum level. Lubiprostone Lubiprostone may decrease the excretion rate of Cisplatin which could result in a higher serum level. Lumiracoxib Lumiracoxib may decrease the excretion rate of Cisplatin which could result in a higher serum level. Macitentan Macitentan may decrease the excretion rate of Cisplatin which could result in a higher serum level. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Cisplatin. Magnesium carbonate Magnesium carbonate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Magnesium chloride Magnesium chloride may decrease the excretion rate of Cisplatin which could result in a higher serum level. Magnesium hydroxide Magnesium hydroxide may decrease the excretion rate of Cisplatin which could result in a higher serum level. Magnesium trisilicate Magnesium trisilicate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Mangafodipir Mangafodipir may decrease the excretion rate of Cisplatin which could result in a higher serum level. Mannitol The risk or severity of nephrotoxicity can be increased when Mannitol is combined with Cisplatin. Maprotiline Maprotiline may decrease the excretion rate of Cisplatin which could result in a higher serum level. Measles virus vaccine The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Cisplatin. Mebeverine The therapeutic efficacy of Mebeverine can be decreased when used in combination with Cisplatin. Mecamylamine Mecamylamine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Mechlorethamine The risk or severity of adverse effects can be increased when Cisplatin is combined with Mechlorethamine. Meclizine The therapeutic efficacy of Meclizine can be decreased when used in combination with Cisplatin. Meclofenamic acid Meclofenamic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. Medroxyprogesterone Medroxyprogesterone acetate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Mefenamic acid Mefenamic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. Megestrol acetate Megestrol acetate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Meloxicam The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Meloxicam. Melphalan The risk or severity of adverse effects can be increased when Cisplatin is combined with Melphalan. Memantine Memantine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Meningococcal The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Cisplatin. Mepenzolate The therapeutic efficacy of Mepenzolate can be decreased when used in combination with Cisplatin. Meperidine Meperidine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Mephenytoin The metabolism of Mephenytoin can be decreased when combined with Cisplatin. Mepivacaine The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Mepivacaine. Mepolizumab The risk or severity of adverse effects can be increased when Cisplatin is combined with Mepolizumab. Meprednisone The therapeutic efficacy of Cisplatin can be decreased when used in combination with Meprednisone. Mercaptopurine The risk or severity of adverse effects can be increased when Cisplatin is combined with Mercaptopurine. Meropenem Meropenem may decrease the excretion rate of Cisplatin which could result in a higher serum level. Mesalazine Mesalazine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Metamfetamine Metamfetamine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Metamizole Metamizole may decrease the excretion rate of Cisplatin which could result in a higher serum level. Metaxalone Metaxalone may decrease the excretion rate of Cisplatin which could result in a higher serum level. Methacholine The risk or severity of adverse effects can be increased when Cisplatin is combined with Methacholine. Methadone Methadone may decrease the excretion rate of Cisplatin which could result in a higher serum level. Methantheline The therapeutic efficacy of Methantheline can be decreased when used in combination with Cisplatin. Methazolamide Methazolamide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. Methimazole The risk or severity of adverse effects can be increased when Cisplatin is combined with Methimazole. Methotrexate The risk or severity of adverse effects can be increased when Cisplatin is combined with Methotrexate. Methotrimeprazine The therapeutic efficacy of Methotrimeprazine can be decreased when used in combination with Cisplatin. Methoxsalen Methoxsalen may decrease the excretion rate of Cisplatin which could result in a higher serum level. Methoxy polyethylene The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Cisplatin. Methoxyflurane The metabolism of Methoxyflurane can be decreased when combined with Cisplatin. Methscopolamine The therapeutic efficacy of Methscopolamine can be decreased when used in combination with Cisplatin. Methscopolamine The therapeutic efficacy of Methscopolamine bromide can be decreased when used in combination with Cisplatin. Methyldopa Methyldopa may decrease the excretion rate of Cisplatin which could result in a higher serum level. Methylene blue The serum concentration of Cisplatin can be increased when it is combined with Methylene blue. Methylnaltrexone Methylnaltrexone may decrease the excretion rate of Cisplatin which could result in a higher serum level. Methylphenobarbital The metabolism of Methylphenobarbital can be decreased when combined with Cisplatin. Methylprednisolone The therapeutic efficacy of Cisplatin can be decreased when used in combination with Methylprednisolone. Methylprednisolone The therapeutic efficacy of Cisplatin can be decreased when used in combination with Methylprednisolone aceponate. Methylprednisolone The therapeutic efficacy of Cisplatin can be decreased when used in combination with Methylprednisolone hemisuccinate. Methyltestosterone Methyltestosterone may decrease the excretion rate of Cisplatin which could result in a higher serum level. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Cisplatin. Muzolimine Muzolimine may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. Mycophenolate mofetil The risk or severity of adverse effects can be increased when Cisplatin is combined with Mycophenolate mofetil. Mycophenolic acid The risk or severity of adverse effects can be increased when Cisplatin is combined with Mycophenolic acid. N-acetyltyrosine N-acetyltyrosine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Nabumetone Nabumetone may decrease the excretion rate of Cisplatin which could result in a higher serum level. Nadolol Nadolol may decrease the excretion rate of Cisplatin which could result in a higher serum level. Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Cisplatin. Naldemedine Naldemedine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Nalmefene Nalmefene may decrease the excretion rate of Cisplatin which could result in a higher serum level. Naloxone Naloxone may decrease the excretion rate of Cisplatin which could result in a higher serum level. Naproxen Naproxen may decrease the excretion rate of Cisplatin which could result in a higher serum level. Natalizumab The risk or severity of adverse effects can be increased when Cisplatin is combined with Natalizumab. Nateglinide Nateglinide may decrease the excretion rate of Cisplatin which could result in a higher serum level. Nebivolol Cisplatin may increase the bradycardic activities of Nebivolol. Nedaplatin Cisplatin may decrease the excretion rate of Nedaplatin which could result in a higher serum level. Nedocromil Nedocromil may decrease the excretion rate of Cisplatin which could result in a higher serum level. Nefazodone Nefazodone may decrease the excretion rate of Cisplatin which could result in a higher serum level. Nelarabine The risk or severity of adverse effects can be increased when Cisplatin is combined with Nelarabine. Neomycin The risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Neomycin. Netilmicin Cisplatin may decrease the excretion rate of Netilmicin which could result in a higher serum level. Nevirapine The metabolism of Nevirapine can be decreased when combined with Cisplatin. Nicardipine The therapeutic efficacy of Nicardipine can be decreased when used in combination with Cisplatin. Nicorandil Nicorandil may decrease the excretion rate of Cisplatin which could result in a higher serum level. Nicotine The serum concentration of Cisplatin can be increased when it is combined with Nicotine. Nifedipine Nifedipine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Nilotinib The risk or severity of adverse effects can be increased when Cisplatin is combined with Nilotinib. Nilutamide Nilutamide may decrease the excretion rate of Cisplatin which could result in a higher serum level. Nimesulide Nimesulide may decrease the excretion rate of Cisplatin which could result in a higher serum level. Nisoldipine Nisoldipine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Nitric Oxide Nitric Oxide may decrease the excretion rate of Cisplatin which could result in a higher serum level. Nitrofurantoin Nitrofurantoin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Nitroprusside Nitroprusside may decrease the excretion rate of Cisplatin which could result in a higher serum level. Norepinephrine The serum concentration of Cisplatin can be increased when it is combined with Norepinephrine. Norgestimate The metabolism of Norgestimate can be decreased when combined with Cisplatin. Nortriptyline The therapeutic efficacy of Nortriptyline can be decreased when used in combination with Cisplatin. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Cisplatin. Obinutuzumab The risk or severity of adverse effects can be increased when Cisplatin is combined with Obinutuzumab. Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Cisplatin. Octinoxate Octinoxate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Ofatumumab The risk or severity of adverse effects can be increased when Cisplatin is combined with Ofatumumab. Olanzapine The therapeutic efficacy of Olanzapine can be decreased when used in combination with Cisplatin. Olaparib The risk or severity of adverse effects can be increased when Cisplatin is combined with Olaparib. Olsalazine Olsalazine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Opium Opium may decrease the excretion rate of Cisplatin which could result in a higher serum level. Orphenadrine The therapeutic efficacy of Orphenadrine can be decreased when used in combination with Cisplatin. Oseltamivir Oseltamivir may decrease the excretion rate of Cisplatin which could result in a higher serum level. Osilodrostat The metabolism of Osilodrostat can be decreased when combined with Cisplatin. Ospemifene The metabolism of Ospemifene can be decreased when combined with Cisplatin. Ouabain Ouabain may decrease the cardiotoxic activities of Cisplatin. Oxacillin Oxacillin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Oxaliplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Oxaliplatin. Oxaprozin Oxaprozin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Oxazepam Oxazepam may decrease the excretion rate of Cisplatin which could result in a higher serum level. Oxetacaine The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Oxetacaine. Oxprenolol The serum concentration of Cisplatin can be increased when it is combined with Oxprenolol. Oxybenzone Oxybenzone may decrease the excretion rate of Cisplatin which could result in a higher serum level. Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Oxybuprocaine. Oxybutynin The therapeutic efficacy of Oxybutynin can be decreased when used in combination with Cisplatin. Oxyphenbutazone Oxyphenbutazone may decrease the excretion rate of Cisplatin which could result in a higher serum level. Oxyphencyclimine The therapeutic efficacy of Oxyphencyclimine can be decreased when used in combination with Cisplatin. Oxyphenonium The therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Cisplatin. Oxyquinoline Oxyquinoline may decrease the excretion rate of Cisplatin which could result in a higher serum level. Ozanimod The risk or severity of adverse effects can be increased when Cisplatin is combined with Ozanimod. Paclitaxel The risk or severity of adverse effects can be increased when Cisplatin is combined with Paclitaxel. Palbociclib The risk or severity of adverse effects can be increased when Cisplatin is combined with Palbociclib. Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Cisplatin. Paliperidone Paliperidone may decrease the excretion rate of Cisplatin which could result in a higher serum level. Palonosetron Palonosetron may decrease the excretion rate of Cisplatin which could result in a higher serum level. Pamidronic acid Pamidronic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. Pancuronium The therapeutic efficacy of Pancuronium can be decreased when used in combination with Cisplatin. Panobinostat The risk or severity of adverse effects can be increased when Cisplatin is combined with Panobinostat. Pantoprazole Pantoprazole may decrease the excretion rate of Cisplatin which could result in a higher serum level. Ranitidine The serum concentration of Cisplatin can be increased when it is combined with Ranitidine. Ranolazine The serum concentration of Cisplatin can be increased when it is combined with Ranolazine. Rapacuronium The therapeutic efficacy of Rapacuronium can be decreased when used in combination with Cisplatin. Rasagiline Rasagiline may decrease the excretion rate of Cisplatin which could result in a higher serum level. Ravulizumab The risk or severity of adverse effects can be increased when Cisplatin is combined with Ravulizumab. Reserpine Reserpine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Resorcinol Resorcinol may decrease the excretion rate of Cisplatin which could result in a higher serum level. Reteplase The risk or severity of bleeding can be increased when Reteplase is combined with Cisplatin. Revefenacin The therapeutic efficacy of Revefenacin can be decreased when used in combination with Cisplatin. Reviparin The risk or severity of bleeding can be increased when Reviparin is combined with Cisplatin. Ribavirin Ribavirin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Ribostamycin Cisplatin may decrease the excretion rate of Ribostamycin which could result in a higher serum level. Rilonacept The risk or severity of adverse effects can be increased when Cisplatin is combined with Rilonacept. Risankizumab The risk or severity of adverse effects can be increased when Cisplatin is combined with Risankizumab. Risedronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Risedronic acid. Rituximab Rituximab may increase the nephrotoxic activities of Cisplatin. Rivaroxaban Rivaroxaban may decrease the excretion rate of Cisplatin which could result in a higher serum level. Rizatriptan Rizatriptan may decrease the excretion rate of Cisplatin which could result in a higher serum level. Rocuronium The therapeutic efficacy of Rocuronium can be decreased when used in combination with Cisplatin. Rofecoxib Rofecoxib may decrease the excretion rate of Cisplatin which could result in a higher serum level. Roflumilast Roflumilast may increase the immunosuppressive activities of Cisplatin. Romidepsin The metabolism of Romidepsin can be decreased when combined with Cisplatin. Ropeginterferon alfa-2b The risk or severity of adverse effects can be increased when Cisplatin is combined with Ropeginterferon alfa-2b. Ropivacaine The risk or severity of methemoglobinemia can be increased when Cisplatin is combined with Ropivacaine. Rosiglitazone Rosiglitazone may decrease the excretion rate of Cisplatin which could result in a higher serum level. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Cisplatin. Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Cisplatin. Ruxolitinib The risk or severity of adverse effects can be increased when Cisplatin is combined with Ruxolitinib. Sacubitril Sacubitril may decrease the excretion rate of Cisplatin which could result in a higher serum level. Salbutamol Salbutamol may decrease the excretion rate of Cisplatin which could result in a higher serum level. Salicylamide Salicylamide may decrease the excretion rate of Cisplatin which could result in a higher serum level. Salicylic acid Salicylic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. Salmeterol The risk or severity of hypokalemia can be increased when Cisplatin is combined with Salmeterol. Salmon calcitonin Salmon calcitonin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Salsalate Salsalate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Sarilumab The risk or severity of adverse effects can be increased when Cisplatin is combined with Sarilumab. Satralizumab The risk or severity of adverse effects can be increased when Cisplatin is combined with Satralizumab. Saxagliptin Saxagliptin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Scopolamine The therapeutic efficacy of Scopolamine can be decreased when used in combination with Cisplatin. Secobarbital Secobarbital may decrease the excretion rate of Cisplatin which could result in a higher serum level. Secukinumab The risk or severity of adverse effects can be increased when Cisplatin is combined with Secukinumab. Selegiline The metabolism of Selegiline can be decreased when combined with Cisplatin. Selenious acid Selenious acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. Selenium Selenium may decrease the excretion rate of Cisplatin which could result in a higher serum level. Sevoflurane The metabolism of Sevoflurane can be decreased when combined with Cisplatin. Sibutramine Sibutramine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Siltuximab The risk or severity of adverse effects can be increased when Cisplatin is combined with Siltuximab. Siponimod The risk or severity of adverse effects can be increased when Cisplatin is combined with Siponimod. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cisplatin. Sirolimus The risk or severity of adverse effects can be increased when Cisplatin is combined with Sirolimus. Sitagliptin Sitagliptin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Smallpox (Vaccinia) The therapeutic efficacy of Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Cisplatin. Sodium acetate Sodium acetate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Sodium aurothiomalate Sodium aurothiomalate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Sodium bisulfite The therapeutic efficacy of Cisplatin can be decreased when used in combination with Sodium bisulfite. Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Cisplatin. Sodium fluoride Sodium fluoride may decrease the excretion rate of Cisplatin which could result in a higher serum level. Sodium sulfate Sodium sulfate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Sofosbuvir Sofosbuvir may decrease the excretion rate of Cisplatin which could result in a higher serum level. Solifenacin The therapeutic efficacy of Solifenacin can be decreased when used in combination with Cisplatin. Solriamfetol Solriamfetol may decrease the excretion rate of Cisplatin which could result in a higher serum level. Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Cisplatin. Sorbitol Sorbitol may decrease the excretion rate of Cisplatin which could result in a higher serum level. Sotalol Cisplatin may increase the bradycardic activities of Sotalol. Spesolimab The risk or severity of adverse effects can be increased when Cisplatin is combined with Spesolimab. Spironolactone Spironolactone may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. Stiripentol Stiripentol may decrease the excretion rate of Cisplatin which could result in a higher serum level. Streptokinase The risk or severity of bleeding can be increased when Streptokinase is combined with Cisplatin. Streptomycin Cisplatin may decrease the excretion rate of Streptomycin which could result in a higher serum level. Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Cisplatin. Strontium chloride Strontium chloride may decrease the excretion rate of Cisplatin which could result in a higher serum level. Succinylcholine The metabolism of Succinylcholine can be decreased when combined with Cisplatin. Sucralfate Sucralfate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Sulbactam Sulbactam may decrease the excretion rate of Cisplatin which could result in a higher serum level. Sulfadiazine Sulfadiazine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Cisplatin. Zonisamide Zonisamide may decrease the excretion rate of Cisplatin which could result in a higher serum level. Zoledronic acid The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Zoledronic acid. Ziprasidone The therapeutic efficacy of Ziprasidone can be decreased when used in combination with Cisplatin. Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Cisplatin. Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Cisplatin. Zanamivir Zanamivir may decrease the excretion rate of Cisplatin which could result in a higher serum level. Zaleplon Zaleplon may decrease the excretion rate of Cisplatin which could result in a higher serum level. Yellow fever vaccine The risk or severity of infection can be increased when Yellow fever vaccine is combined with Cisplatin. Ximelagatran The risk or severity of bleeding can be increased when Ximelagatran is combined with Cisplatin. Warfarin Cisplatin may decrease the excretion rate of Warfarin which could result in a higher serum level. Voxelotor The metabolism of Voxelotor can be decreased when combined with Cisplatin. Vortioxetine Vortioxetine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Vorinostat The risk or severity of adverse effects can be increased when Cisplatin is combined with Vorinostat. Vorapaxar The risk or severity of bleeding can be increased when Vorapaxar is combined with Cisplatin. Voclosporin The risk or severity of adverse effects can be increased when Cisplatin is combined with Voclosporin. Vinorelbine The risk or severity of adverse effects can be increased when Cisplatin is combined with Vinorelbine. Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Cisplatin. Vincristine The risk or severity of adverse effects can be increased when Cisplatin is combined with Vincristine. Vinblastine The risk or severity of adverse effects can be increased when Cisplatin is combined with Vinblastine. Viloxazine Viloxazine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Vilanterol The risk or severity of adverse effects can be increased when Cisplatin is combined with Vilanterol. Vibrio cholerae The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Cisplatin. Verapamil Verapamil may decrease the excretion rate of Cisplatin which could result in a higher serum level. Venlafaxine Venlafaxine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Velpatasvir The metabolism of Velpatasvir can be decreased when combined with Cisplatin. Vedolizumab The risk or severity of adverse effects can be increased when Cisplatin is combined with Vedolizumab. Vecuronium The therapeutic efficacy of Vecuronium can be decreased when used in combination with Cisplatin. Varicella zoster vaccine The therapeutic efficacy of Varicella zoster vaccine (recombinant) can be decreased when used in combination with Cisplatin. Varicella zoster vaccine The risk or severity of infection can be increased when Varicella zoster vaccine (live/attenuated) is combined with Cisplatin. Varenicline The excretion of Varenicline can be decreased when combined with Cisplatin. Vandetanib The serum concentration of Cisplatin can be increased when it is combined with Vandetanib. Vancomycin Vancomycin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Valproic acid The metabolism of Valproic acid can be decreased when combined with Cisplatin. Valganciclovir Valganciclovir may decrease the excretion rate of Cisplatin which could result in a higher serum level. Valdecoxib Valdecoxib may decrease the excretion rate of Cisplatin which could result in a higher serum level. Valbenazine Valbenazine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Valaciclovir Valaciclovir may decrease the excretion rate of Cisplatin which could result in a higher serum level. Vaborbactam Vaborbactam may decrease the excretion rate of Cisplatin which could result in a higher serum level. Urokinase The risk or severity of bleeding can be increased when Urokinase is combined with Cisplatin. Upadacitinib The risk or severity of adverse effects can be increased when Cisplatin is combined with Upadacitinib. Umeclidinium The therapeutic efficacy of Umeclidinium can be decreased when used in combination with Cisplatin. Typhoid Vi The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Cisplatin. Typhoid Vaccine Live The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Cisplatin. Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Cisplatin. Tucatinib The serum concentration of Cisplatin can be increased when it is combined with Tucatinib. Tubocurarine Cisplatin may increase the neuromuscular blocking activities of Tubocurarine. Trospium The therapeutic efficacy of Trospium can be decreased when used in combination with Cisplatin. Tropisetron Tropisetron may decrease the excretion rate of Cisplatin which could result in a higher serum level. Trimetrexate Trimetrexate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Trimethoprim The serum concentration of Cisplatin can be increased when it is combined with Trimethoprim. Trimethaphan Cisplatin may increase the neuromuscular blocking activities of Trimethaphan. Trimebutine Trimebutine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Trilostane The therapeutic efficacy of Cisplatin can be decreased when used in combination with Trilostane. Trilaciclib The risk or severity of nephrotoxicity can be increased when Trilaciclib is combined with Cisplatin. Trihexyphenidyl The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Cisplatin. Triflusal The risk or severity of bleeding can be increased when Triflusal is combined with Cisplatin. Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Cisplatin. Triflupromazine The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Cisplatin. Triethylenetetramine Triethylenetetramine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Trichlormethiazide Trichlormethiazide may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. Triazolam Triazolam may decrease the excretion rate of Cisplatin which could result in a higher serum level. Triamterene Triamterene may decrease the excretion rate of Cisplatin which could result in a higher serum level. Triamcinolone The therapeutic efficacy of Cisplatin can be decreased when used in combination with Triamcinolone. Tretinoin The risk or severity of adverse effects can be increased when Cisplatin is combined with Tretinoin. Trastuzumab emtansine The risk or severity of adverse effects can be increased when Cisplatin is combined with Trastuzumab emtansine. Trastuzumab Trastuzumab may increase the neutropenic activities of Cisplatin. Trametinib Trametinib may decrease the excretion rate of Cisplatin which could result in a higher serum level. Tramadol Tramadol may decrease the excretion rate of Cisplatin which could result in a higher serum level. Trabectedin The risk or severity of adverse effects can be increased when Cisplatin is combined with Trabectedin. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Cisplatin. Torasemide The risk or severity of ototoxicity and nephrotoxicity can be increased when Torasemide is combined with Cisplatin. Topotecan The risk or severity of adverse effects can be increased when Cisplatin is combined with Topotecan. Topiramate Topiramate may decrease the excretion rate of Cisplatin which could result in a higher serum level. Tolvaptan Tolvaptan may increase the excretion rate of Cisplatin which could result in a lower serum level and potentially a reduction in efficacy. Tolterodine Tolterodine may decrease the excretion rate of Cisplatin which could result in a higher serum level. Tolmetin Tolmetin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Tolfenamic acid Tolfenamic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. Tolcapone Tolcapone may decrease the excretion rate of Cisplatin which could result in a higher serum level. Tolbutamide Tolbutamide may decrease the excretion rate of Cisplatin which could result in a higher serum level. Tolazamide Tolazamide may decrease the excretion rate of Cisplatin which could result in a higher serum level. Tofacitinib Cisplatin may increase the immunosuppressive activities of Tofacitinib. Tocopherol Tocopherol may decrease the excretion rate of Cisplatin which could result in a higher serum level. Tocilizumab The risk or severity of adverse effects can be increased when Cisplatin is combined with Tocilizumab. Tobramycin Cisplatin may decrease the excretion rate of Tobramycin which could result in a higher serum level. Tixocortol The therapeutic efficacy of Cisplatin can be decreased when used in combination with Tixocortol. Tirofiban Tirofiban may decrease the excretion rate of Cisplatin which could result in a higher serum level. Tipiracil The excretion of Tipiracil can be decreased when combined with Cisplatin. Tiotropium Tiotropium may decrease the excretion rate of Cisplatin which could result in a higher serum level. Tiopronin Tiopronin may decrease the excretion rate of Cisplatin which could result in a higher serum level. Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Cisplatin. Tinzaparin The risk or severity of bleeding can be increased when Tinzaparin is combined with Cisplatin. Tinidazole Tinidazole may decrease the excretion rate of Cisplatin which could result in a higher serum level. Timolol Timolol may decrease the excretion rate of Cisplatin which could result in a higher serum level. Tiludronic acid Tiludronic acid may decrease the excretion rate of Cisplatin which could result in a higher serum level. Pregnancy and Lactation FDA Pregnancy category D Pregnancy There is a possibility of birth defects if either the man or woman is using cisplatin at the time of conception, or if it is taken during pregnancy. This medication should not be used during pregnancy unless the benefits outweigh the risks. Use effective birth control while you are being treated with this medication. If you become pregnant while taking this medication, contact your doctor immediately. Breast-feeding This medication passes into breast milk. Women receiving this medication should not breastfeed. How should this medicine be used?

Cisplatin injection comes as a solution (liquid) to be injected over 6 to 8 hours intravenously (into a vein) by a doctor or nurse in a medical facility. It is usually given once every 3 to 4 weeks.

References

Add references, clinical guidelines, textbooks, journal articles, or trusted medical sources here. You can edit this area from the RX Article Professional Blocks panel.

More from this topic
  1. Vasodilator Drugs

    Vasodilator drugs relax and widen blood vessels, increasing blood flow. A few examples include ACE inhibitors, ARBs, calcium channel blockers, and nitrates.   DefinitionVasodilators are medicines that dilate...

    June 9, 2025 • Drugs (A - Z)
  2. Methamphetamine Hydrochloride – Uses, Dosage, Side Effects, Interaction

    Methamphetamine Hydrochloride is the hydrochloride salt form of methamphetamine, an amphetamine and sympathomimetic amine with CNS stimulating properties. Methamphetamine hydrochloride acts by facilitating the release of catecholamines, particularly noradrenaline and dopamine, from...

    June 5, 2025 • Drugs (A - Z)
  3. Methamphetamine – Uses, Dosage, Side Effects, Interactions

    Methamphetamine is a member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent. It has a role as a neurotoxin, a psychotropic drug,...

    June 5, 2025 • Drugs (A - Z)
  4. Vitamin D3 – Uses, Dosage, Side Effects, Interactions

    DefinitionCholecalciferol is a steroid? hormone produced in the skin when exposed to ultraviolet light or obtained from dietary sources. The active form of cholecalciferol, 1,25-dihydroxycholecalciferol (calcitriol) plays an important role...

    March 10, 2025 • Drugs (A - Z)
  5. Imidazole – Uses, Dosage, Side Effects, Interactions

    DefinitionImidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is...

    October 20, 2023 • Drugs (A - Z)
  6. Carbimazole

    Carbimazole is a member of the class of imidazoles that is methimazole in which the nitrogen-bearing hydrogen is converted into its methoxycarbonyl derivative. A prodrug for methimazole, carbimazole is...

    October 20, 2023 • Drugs (A - Z)
  7. Methylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionA thiourea antithyroid agent that inhibits the synthesis of thyroid? hormone. It is used in the treatment of hyperthyroidism?. Methylthiouracil is an organosulfur compound that is used in...

    October 20, 2023 • Drugs (A - Z)
  8. Propylthiouracil – Uses, Dosage, Side Effects, Interactions

    DefinitionPropylthiouracil is a Thyroid? Hormone Synthesis Inhibitor. The mechanism of action of propylthiouracil is as a Thyroid Hormone Synthesis Inhibitor. 6-propyl-2-thiouracil is a pyrimidine-thione consisting of uracil in which the...

    October 20, 2023 • Drugs (A - Z)
  9. Methimazole

    DefinitionMethimazole ( Metirox 5 and 10 mg) is a member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen that is attached to...

    October 20, 2023 • Drugs (A - Z)
  10. Mirogabalin – Uses, Dosage, Side Effects, Interactions

    DefinitionMirogabalin has been used in trials studying the treatment of Post-herpetic Neuralgia, Pain? Associated With Fibromyalgia, and Diabetic peripheral neuropathic pain. Mirogabalin is a medication designed...

    August 12, 2023 • Drugs (A - Z)